Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 2,082 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open Label Extension Study Clear all
Active, not recruiting Phase 3 Interventional

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05809531
View directory record Official record
Conditions
C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Gainsville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 31, 2026, 11:09 PM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

NCT00411099
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
agomelatine, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
42
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Cerritos, California + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 31, 2026, 11:09 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain

NCT01920087
View directory record Official record
Conditions
Atypical Facial Pain, Persistent Idiopathic Facial Pain, Atypical Trigeminal Neuralgia, Neuropathic Orofacial Pain, Neuropathic Facial Pain
Interventions
ATNC05, Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 31, 2026, 11:09 PM EDT
Completed Phase 2 Interventional

Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC

NCT05059327
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
Basimglurant with crossover to Placebo, Placebo with crossover to Basimglurant
Drug
Lead sponsor
Noema Pharma AG
Industry
Eligibility
5 Years to 30 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 31, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

NCT01118962
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 31, 2026, 11:09 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

NCT04592341
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Gantenerumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Atlantis, Florida • Maitland, Florida • Ocala, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 31, 2026, 11:09 PM EDT
Withdrawn Phase 3 Interventional

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

NCT05219864
View directory record Official record
Conditions
Hand Eczema
Interventions
Ruxolitinib cream, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Encino, California • Fountain Valley, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 31, 2026, 11:09 PM EDT
Completed Phase 4 Interventional Results available

EASY: Extended Access to Sollpura Over Years

NCT02823964
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
Liprotamase
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Aurora, Colorado • Jackson, Mississippi • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 31, 2026, 11:09 PM EDT
Recruiting Phase 2 Interventional

Open-label Extension Study in Participants With Early Alzheimer's Disease

NCT07105709
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
GSK4527226
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Maitland, Florida • Miami, Florida • Stuart, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 31, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)

NCT03577171
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H0731, SOC ETV, Placebo Oral Tablet
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Coronado, California • Los Angeles, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 31, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

NCT02847637
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab, Factor VIII (FVIII)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
8
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 31, 2026, 11:09 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

NCT07058077
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia (HeFH)
Interventions
Enlicitide Decanoate, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
8
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 31, 2026, 11:09 PM EDT
Completed Phase 2 Interventional

Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)

NCT01557777
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Navitoclax
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Pleasant Hill, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 31, 2026, 11:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Soft Contact Lens Use With 7 Day Extended Wear

NCT00597467
View directory record Official record
Conditions
Ametropia
Interventions
VISA (comfilcon A) Silicone Hydrogel Soft contact lens, Acuvue 2 Soft Contact Lens
Device
Lead sponsor
CooperVision, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
23
States / cities
La Mesa, California • San Diego, California • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 31, 2026, 11:09 PM EDT
Terminated Phase 2 Interventional

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

NCT04905212
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Telitacicept 160mg, Telitacicept 240mg, Placebo
Drug
Lead sponsor
RemeGen Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 31, 2026, 11:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers

NCT06167265
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Cilostazol Tablet 100 mg, PMR Tablet 145 mg
Drug
Lead sponsor
Genovate Biotechnology Co., Ltd.,
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 31, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension

NCT01642212
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Oral Budesonide Suspension (MB-9), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
11 Years to 40 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
23
States / cities
Phoenix, Arizona • Orange, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 31, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

NCT00359281
View directory record Official record
Conditions
Healthy
Interventions
atorvastatin, simvastatin, ezetimibe, fenofibrate, dextromethorphan, Extended Release Niacin
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 31, 2026, 11:09 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

NCT06456580
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Telitacicept, Placebo
Biological · Drug
Lead sponsor
Vor Biopharma
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
30
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 11:09 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
PF-07868489
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 11:09 PM EDT
Withdrawn Phase 3 Interventional

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

NCT05233410
View directory record Official record
Conditions
Chronic Hand Eczema (CHE)
Interventions
Ruxolitinib cream, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Huntington Beach, California • Westminster, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 31, 2026, 11:09 PM EDT
Completed Phase 2 Interventional

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

NCT02064426
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Molidustat (BAY85-3934), Epoetin alfa/beta
Drug · Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Azusa, California • Long Beach, California • Lynwood, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 31, 2026, 11:09 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection

NCT01651403
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Tenofovir DF, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 11 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
5
States / cities
Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 31, 2026, 11:09 PM EDT
Recruiting Phase 2 Interventional

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

NCT06817889
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease, Respiratory Syncytial Virus Infection
Interventions
Remdesivir, Survey Administration, Biospecimen Collection, Nasal Swab
Drug · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Duarte, California • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 11:09 PM EDT